Abstract
Understanding the molecular events that commit to the cell cycle has important implications for cancer. Available evidence, mostly derived from human tumors, has revealed frequent alterations in genes involved in the control of the G1 restriction point and the progression from G1 to S phase. Many of the players that participate in these events have been characterized at the biochemical level. They include, among others the cyclin-dependent kinases (Cdk), Cdk4, Cdk6 and Cdk2 and their cognate D- and E-type cyclins, Cdk inhibitors (CKI), and the main Cdk downstream substrates, the retinoblastoma (pRb) family of proteins. Yet, there is little information as how these molecules regulate cell cycle commitment in vivo. The development of mouse strains carrying targeted mutations in these loci is opening new ways to explore the network of molecular pathways that control passage through G1 into the S phase in complex multicellular organisms such as mammals. These strains are also providing new insights as of how misregulation of these processes may lead to cancer development. In this review, we attempt to summarize our current knowledge of the molecular mechanisms that control the G1 / S transition with particular emphasis in those studies carried out in vivo using gene targeted mice.
Keywords: gi restriction, transition, cdk inhibitor, cdku,cdk6, cdk2
Current Genomics
Title: Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition
Volume: 3 Issue: 4
Author(s): S. Ortega, M. Malumbres and M. Barbacid
Affiliation:
Keywords: gi restriction, transition, cdk inhibitor, cdku,cdk6, cdk2
Abstract: Understanding the molecular events that commit to the cell cycle has important implications for cancer. Available evidence, mostly derived from human tumors, has revealed frequent alterations in genes involved in the control of the G1 restriction point and the progression from G1 to S phase. Many of the players that participate in these events have been characterized at the biochemical level. They include, among others the cyclin-dependent kinases (Cdk), Cdk4, Cdk6 and Cdk2 and their cognate D- and E-type cyclins, Cdk inhibitors (CKI), and the main Cdk downstream substrates, the retinoblastoma (pRb) family of proteins. Yet, there is little information as how these molecules regulate cell cycle commitment in vivo. The development of mouse strains carrying targeted mutations in these loci is opening new ways to explore the network of molecular pathways that control passage through G1 into the S phase in complex multicellular organisms such as mammals. These strains are also providing new insights as of how misregulation of these processes may lead to cancer development. In this review, we attempt to summarize our current knowledge of the molecular mechanisms that control the G1 / S transition with particular emphasis in those studies carried out in vivo using gene targeted mice.
Export Options
About this article
Cite this article as:
Ortega S., Malumbres M. and Barbacid M., Cell Cycle and Cancer: The G1 Restriction Point and the G1 / S Transition, Current Genomics 2002; 3 (4) . https://dx.doi.org/10.2174/1389202023350444
DOI https://dx.doi.org/10.2174/1389202023350444 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics
Mini-Reviews in Medicinal Chemistry RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Amaranth: A Pseudo-Cereal with Nutraceutical Properties
Current Nutrition & Food Science Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Metabolomics Applications in Precision Medicine: An Oncological Perspective
Current Topics in Medicinal Chemistry CXCR7 Participates in CXCL12-mediated Cell Cycle and Proliferation Regulation in Mouse Neural Progenitor Cells
Current Molecular Medicine Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease
Combinatorial Chemistry & High Throughput Screening Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Aberrant DNA Methylation and Prostate Cancer
Current Genomics Corneal Neovascularization: Molecular Events and Therapeutic Options
Recent Patents on Inflammation & Allergy Drug Discovery Activation of Myosin Phosphatase by Epigallocatechin-Gallate Sensitizes THP-1 Leukemic Cells to Daunorubicin
Anti-Cancer Agents in Medicinal Chemistry Current Evidence and Potential Mechanisms of Therapeutic Action of PEDF in Cervical Cancer Treatment
Current Molecular Medicine PP-1α and PP-1γ Display Antagonism and Differential Roles in Tumorigenicity of Lung Cancer Cells
Current Molecular Medicine Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology